SCHEMBL496975

SCHEMBL496975

O=C(c1ccccc1)n1ncc2ccccc21

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 5/20 0.70
SLC22A12 Q96S37 2/20 0.66
KMT2A Q03164 4/20 0.51
F2 P00734 3/20 0.51
HPGD P15428 3/20 0.51
MGAM O43451 1/20 0.51
AMY1A P0DUB6 1/20 0.51
GAA P10253 1/20 0.51
SI P14410 1/20 0.51
SLC9A1 P19634 1/20 0.51
MGAM2 Q2M2H8 1/20 0.51
RAB9A P51151 2/20 0.50
TFPI2 P48307 1/20 0.50
TSHR P16473 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
ASAH1 Q13510 2/20 0.49
KMO O15229 1/20 0.49
CYP1A2 P05177 1/20 0.45
MAPT P10636 1/20 0.45
CYP2C9 P11712 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29238955 0.98 ELANE (0.68) ELANESLC22A12KMT2AF2HPGD
SCHEMBL260982 0.83 SLC22A12 (0.54) ELANESLC22A12KMT2ARAB9ATFPI2
Hydrochloric Acid SCHEMBL30581596 0.81 SLC22A12 (0.53) ELANESLC22A12KMT2ARAB9ATFPI2
SCHEMBL5433163 0.81 ELANE (0.53) ELANESLC22A12KMT2AF2HPGD
SCHEMBL4423022 0.81 SLC22A12 (0.55) ELANESLC22A12KMT2ARAB9ATFPI2
SCHEMBL29898250 0.80 SLC22A12 (1.00) ELANESLC22A12MGAMAMY1AGAA
SCHEMBL6201897 0.79 ELANE (0.51) ELANESLC22A12KMT2AF2HPGD
SCHEMBL11311967 0.78 PLA2G10 (0.55) ELANESLC22A12KMT2AF2HPGD
Indazole Carboxamide SCHEMBL42505 0.78 SLC22A12 (0.53) ELANESLC22A12KMT2ARAB9ATFPI2
SCHEMBL1087434 0.78 CHEK1 (0.60) ELANESLC22A12KMT2ARAB9ATFPI2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116606246-A Silver complex antibacterial agent with aromatic amide structure-containing nitrogen heterocyclic derivative as ligand, and preparation method and application thereof 烟台哈尔滨工程大学研究院 2023-08-18 CN disclosed
US-8198298-B2 Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2012-06-12 US disclosed
US-8106069-B2 Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors and pharmaceutical compositions comprising them PFIZER ITALIA S.R.L. (IT) 2012-01-31 US disclosed
US-20110136857-A1 PYRROLE[2,3-B]PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS PFIZER ITALIA S.R.L. (IT) 2011-06-09 US disclosed
US-7888508-B2 3-(carboxy or carbamoyl)-5-amino-1H-pyrrolo(2,3-b)pyridines; cancer, Alzheimer's disease, viral infections, autoimmune diseases and neurodegenerative disorders; chemical libraries of these compounds PFIZER ITALIA S.R.L. (IT) 2011-02-15 US disclosed
US-20100210476-A1 Pyrrolo[2,3-b]Pyridine Derivatives Active as Kinase Inhibitors and Pharmaceutical Compositions Comprising Them PFIZER ITALIA S.R.L. (IT) 2010-08-19 US disclosed
US-7728140-B2 Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors and pharmaceutical compositions comprising them PFIZER ITALIA S.R.L. (IT) 2010-06-01 US disclosed
EP-1701956-B1 PYRROLO[2,3-B]PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM PFIZER ITALIA SRL (IT) 2010-02-24 EP disclosed
EP-1704147-B1 PYRROLO[2,3-b] PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION COMPRISING THEM PFIZER ITALIA SRL (IT) 2009-11-04 EP disclosed
CN-100396678-C Synthesis and use of indole analogues of 1-benzyl-3- (5 '-hydroxymethyl-2' -furyl) indazole IND TECH RES INST (CN) 2008-06-25 CN disclosed
US-7176230-B2 Synthesis of indole analogs of 1-benzyl-3-(5′-hydroxymethyl-2′-furyl) indazole (YC-1) as anti-platelet agents INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) 2007-02-13 US disclosed
EP-1701956-A1 PYRROLO[2,3-B]PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM Pfizer Italia S.r.l. (IT) 2006-09-20 EP disclosed
CN-1827616-A Synthesis and use of indole analogues of 1-benzyl-3- (5 '-hydroxymethyl-2' -furyl) indazole IND TECH RES INST (CN) 2006-09-06 CN disclosed
US-20060106041-A1 Synthesis of indole analogs of 1-benzyl-3-(5'-hydroxymethy 1-2' -furyl) indazole (YC-1) as anti-platelet agents INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) 2006-05-18 US disclosed
US-20050256151-A1 Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them PHARMACIA ITALIA S.P.A. (IT) 2005-11-17 US disclosed
US-20050209269-A1 Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them PHARMACIA ITALIA S.P.A. (IT) 2005-09-22 US disclosed
WO-2005063746-A1 PYRROLO[2,3-b]PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM PFIZER ITALIA S.R.L. (IT) 2005-07-14 WO disclosed
EP-0135781-B1 3-(PIPERIDINYL)- AND 3-(PYRROLIDINYL)-1H-INDAZOLES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS A MEDICAMENT HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1989-10-11 EP disclosed
EP-0192935-A1 3-(piperidinyl)-1H-indazoles a process for their preparation and their use as medicaments HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1986-09-03 EP disclosed
EP-0135781-A1 3-(Piperidinyl)- and 3-(pyrrolidinyl)-1H-indazoles, a process for their preparation and their use as a medicament HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1985-04-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100210476-A1 Pyrrolo[2,3-b]Pyridine Derivatives Active as Kinase Inhibitors and Pharmaceutical Compositions Comprising Them MAP3K6, MAP3K3, MAP3K1 ELANE 4747/4885SLC22A12 4847/4885KMT2A 1717/4885
US-20060106041-A1 Synthesis of indole analogs of 1-benzyl-3-(5'-hydroxymethy 1-2' -furyl) indazole (YC-1) as anti-platelet agents PFKP, HMOX1, TPH1 ELANE 2497/4885SLC22A12 4729/4885KMT2A 2910/4885
US-20050256151-A1 Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them MAP3K6, MAP3K3, MAP3K1 ELANE 4801/4885SLC22A12 4864/4885KMT2A 1599/4885
US-20110136857-A1 PYRROLE[2,3-B]PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS MAP3K6, MAP3K3, MAP3K15 ELANE 4734/4885SLC22A12 4850/4885KMT2A 1503/4885
US-20050209269-A1 Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them MAP3K6, MAP3K3, MAP3K1 ELANE 4801/4885SLC22A12 4864/4885KMT2A 1599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.